Last price paid | 0.20 | |
Change | -9.09% [ -0.02 ] | |
Last traded volume | n.a. Unit | |
Cumulative volume | n.a. Unit | |
Date/time | 02.08.2024 17:20 |
Fixing | n.a. |
Settlement date | 23.05.2024 |
Last trading | n.a. |
Final fixing | n.a. |
Currency redemption | CHF |
Perf. since issue | -22.00% |
Year to date (YTD) | n.a. |
1 month | -56.52% |
3 months | n.a. |
1 year | n.a. |
3 years | n.a. |
Issue price | 0.25 |
Underlying price on issue | 911.80 |
Premium | 0.05% |
Premium p.a. | n.a. |
Leverage | n.a. |
Implied volatility | n.a. |
ISIN | CH1338503704 |
Symbol | INOLYZ |
Security | 133850370 |
Exchange | SIX Structured Products |
Currency | CHF |
Expiry | n.a. |
Underlying | Novo Nordisk -B-, DK0062498333 |
Underlying ISIN | DK0062498333 |
Funding level | 833.678000 |
Stop-loss level | 866.487400 |
Distance to stop-loss level | 0.55% |
Long/Short type | Long |
Subscription ratio | 50.00 |
Issuer | Zürcher Kantonalbank |
Exercise type | n.a. |
Minimum execution | n.a. |
Value day | 21.05.2024 |
Premium | 4.52% |
Premium p.a. | n.a. |
Leverage | 11.24 |
Moneyness | in-the-money |
Leverage | n.a. |
Delta | n.a. |
Intrinsic value | 38.139100 |
Break-even | n.a. |
SSPA value at risk | n.a. |
SSPA risk rating | n.a. |
SSPA derivative category | Leverage |
SSPA code | Mini future (2210) |
Redemption date | 12.08.2024 |
Redemption amount | 0.0286 |
Name | Price |
---|---|
UBS | 24.72 |
NOVARTIS N | 96.74 |
Holcim | 76.18 |
Sika AG | 248.40 |
Partners Group Ho... | 1'115.50 |
Name | Price |
---|---|
SWISSCOM N | 521.50 |
Givaudan | 4'140.00 |
Nestlé SA | 89.28 |
GEBERIT N | 526.80 |
Compagnie Financi... | 125.35 |